<DOC>
	<DOCNO>NCT00176813</DOCNO>
	<brief_summary>This study examine investigational ( experimental ) treatment use gemcitabine , cisplatin , celecoxib . Preliminary study show experimental treatment may effective reduce size cancerous tumor and/or prevent tumor growth . This phase II clinical trial study reaction patient 's body tumor combination gemcitabine , cisplatin , celecoxib . The purpose study see tumor responds treatment determine long response last . This study also look kind side effect experimental treatment cause see often side effect occur . Blood level celecoxib measure find treatment affect factor ( protein ) involve new blood vessel formation tumor growth ( angiogenesis ) .</brief_summary>
	<brief_title>Gemcitabine , Cisplatin , Celecoxib Treatment Metastatic Pancreatic Cancer</brief_title>
	<detailed_description />
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>Inclusion Criteria 1 . Patients must histologic cytologic diagnosis pancreatic adenocarcinoma . 2 . Patients must clinical/radiologic evidence metastatic disease ( stage IV ) . 3 . Patients must receive prior chemotherapy metastatic disease . Prior adjuvant chemotherapy allow , provide last day therapy least 6 month prior start treatment . 4 . Patients must performance status 02 SWOG scale . 5 . Patients must estimate life expectancy least 12 week . 6 . Patients must adequate bone marrow function : absolute neutrophil count &gt; 1,500/cmm , platelet count &gt; 100,000/cmm . 7 . Patients must inform investigational nature study must give write informed consent prior receive treatment per protocol . 8 . Patients must practice effective birth control receive treatment . Exclusion Criteria 1 . Patients endocrine tumor lymphoma pancreas . 2 . Patients locally advanced pancreatic cancer . 3 . Patients proven history ( radiographic and/or endoscopic ) peptic ulcer esophageal erosion within one year enrollment onto study . 4 . Patients experience asthma , urticaria , allergictype reaction take aspirin nonsteroidal antiinflammatory drug . 5 . History active central nervous system ( CNS ) metastases . 6 . Inadequate liver function ( bilirubin &gt; 3.0 mg/dL ) ; transaminase ( AST/ALT ) &gt; 3 time upper limit institutional normal . 7 . Inadequate renal function ( creatinine &gt; 1.5 mg/dL ) . 8 . Serious concomitant systemic disorder incompatible study ( discretion investigator ) . 9 . History malignancy , except cancer treat curative intent patient without evidence active disease . 10 . Unresolved bacterial infection require treatment antibiotic . 11 . Pregnant lactate woman may participate study . 12 . Patients allergy study drug sulfa drug . 13 . Patients infected HIV1 virus undetermined effect chemotherapy regimen patient HIV1 potential serious interaction antiHIV medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
</DOC>